Zimmer Biomet (ZBH) appointed Jonathan Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand Murthi, MD, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma. Vigdorchik is a board-certified, fellowship-trained orthopaedic surgeon at Hospital for Special Surgery in New York City, specializing in hip and knee replacement surgery. Murthi is a board-certified, fellowship-trained orthopaedic surgeon who serves as Chief of Shoulder and Elbow Surgery and Director of the Shoulder and Elbow Fellowship Program at MedStar Union Memorial Hospital in Baltimore, Md. In these roles, Vigdorchik and Murthi will assist with medical education and surgeon engagement; advise on the company’s technology and implant strategy and development roadmap; and serve as strategic liaisons between Zimmer Biomet and the broader surgical community.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet’s Strong Q2 Performance and Optimistic Outlook
- Zimmer Biomet price target raised to $125 from $115 at Baird
- Zimmer Biomet price target raised to $113 from $104 at Raymond James
- Zimmer Biomet price target raised to $96 from $91 at UBS
- Zimmer Biomet Holdings: Balancing Strong Segment Growth with US Knee Challenges – Hold Rating Maintained